1
|
The deubiquitinase USP10 protects pancreatic cancer cells from endoplasmic reticulum stress. NPJ Precis Oncol 2022; 6:93. [PMID: 36543867 PMCID: PMC9772324 DOI: 10.1038/s41698-022-00336-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 11/29/2022] [Indexed: 12/24/2022] Open
Abstract
The ubiquitin-specific peptidase 10 (USP10) plays a context-specific, pro or anti-tumorigenic role in different malignancies. However, the role of USP10 in pancreatic cancer remains unclear. Our protein and RNA level analysis from archived specimens and public databases show that USP10 is overexpressed in pancreatic ductal adenocarcinoma (PDAC) and expression correlates with poor overall patient survival. Phenotypically, silencing USP10 decreased viability, clonal growth and invasive properties of pancreatic cancer cells. Mechanistically, silencing USP10 upregulated BiP and induced endoplasmic reticulum (ER) stress that led to an unfolded protein response (UPR) and upregulation of PERK, IRE1α. Decreased cell viability of USP10 silenced cells could be rescued by a chemical chaperone that promotes protein folding. Our studies suggest that USP10 by protecting pancreatic cancer cells from ER stress may support tumor progression.
Collapse
|
2
|
KRCC1, a modulator of the DNA damage response. Nucleic Acids Res 2022; 50:11028-11039. [PMID: 36243983 PMCID: PMC9638924 DOI: 10.1093/nar/gkac890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 09/27/2022] [Accepted: 10/03/2022] [Indexed: 11/13/2022] Open
Abstract
The lysine-rich coiled-coil 1 (KRCC1) protein is overexpressed in multiple malignancies, including ovarian cancer, and overexpression correlates with poor overall survival. Despite a potential role in cancer progression, the biology of KRCC1 remains elusive. Here, we characterize the biology of KRCC1 and define its role in the DNA damage response and in cell cycle progression. We demonstrate that KRCC1 associates with the checkpoint kinase 1 (CHK1) upon DNA damage and regulates the CHK1-mediated checkpoint. KRCC1 facilitates RAD51 recombinase foci formation and augments homologous recombination repair. Furthermore, KRCC1 is required for proper S-phase progression and subsequent mitotic entry. Our findings uncover a novel component of the DNA damage response and a potential link between cell cycle, associated damage response and DNA repair.
Collapse
|
3
|
Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS JOURNAL 2020; 22:51. [PMID: 32086622 DOI: 10.1208/s12248-020-0421-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Accepted: 01/08/2020] [Indexed: 12/11/2022]
Abstract
The orally available novel small molecule SHetA2 is the lead sulfur-containing heteroarotinoid that selectively inhibits cancer cells over normal cells, and is currently under clinical development for anticancer treatment and cancer prevention. The objective of this study was to assess and characterize the tissue distribution of SHetA2 in tumor-bearing mice by developing a physiologically based pharmacokinetic (PBPK) model. An orthotopic SKOV3 ovarian cancer xenograft mouse model was used to most accurately mimic the ovarian cancer tumor microenvironment in the peritoneal cavity. SHetA2 concentrations in plasma and 14 different tissues were measured at various time points after a single intravenous dose of 10 mg/kg and oral dose of 60 mg/kg, and these data were used to develop a whole-body PBPK model. SHetA2 exhibited a multi-exponential plasma concentration decline with an elimination half-life of 4.5 h. Rapid and extensive tissue distribution, which was best described by a perfusion rate-limited model, was observed with the tissue-to-plasma partition coefficients (kp = 1.4-21.2). The PBPK modeling estimated the systemic clearance (76.4 mL/h) from circulation as a main elimination pathway of SHetA2. It also indicated that the amount absorbed into intestine was the major determining factor for the oral bioavailability (22.3%), while the first-pass loss from liver and intestine contributed minimally (< 1%). Our results provide an insight into SHetA2 tissue distribution characteristics. The developed PBPK model can be used to predict the drug exposure at tumors or local sites of action for different dosing regimens and scaled up to humans to correlate with efficacy.
Collapse
|
4
|
HER2/HER3 regulates lactate secretion and expression of lactate receptor mRNA through the MAP3K4 associated protein GIT1. Sci Rep 2019; 9:10823. [PMID: 31346208 PMCID: PMC6658559 DOI: 10.1038/s41598-019-46954-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 07/03/2019] [Indexed: 12/16/2022] Open
Abstract
One of the major features of cancer is Otto Warburg’s observation that many tumors have increased extracellular acidification compared to healthy tissues. Since Warburg’s observation, the importance of extracellular acidification in cancer is now considered a hallmark of cancer. Human MAP3K4 functions upstream of the p38 and JNK mitogen activated protein kinases (MAPKs). Additionally, MAP3K4 is required for cell migration and extracellular acidification of breast cancer cells in response to HER2/HER3 signaling. Here, we demonstrate that GIT1 interacts with MAP3K4 by immunoprecipitation, while cellular lactate production and the capacity of MCF-7 cells for anchorage independent growth in soft agar were dependent on GIT1. Additionally, we show that activation of HER2/HER3 signaling leads to reduced expression of lactate receptor (GPR81) mRNA and that both, GIT1 and MAP3K4, are necessary for constitutive expression of GPR81 mRNA. Our study suggests that targeting downstream proteins in the HER2/HER3-induced extracellular lactate signaling pathway may be a way to inhibit the Warburg Effect to disrupt tumor growth.
Collapse
|
5
|
Vitamin D, leptin, vitamin D receptor single nucleotide polymorphism and treatment-related morbidity in ovarian, primary peritoneal, and fallopian tube cancer. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.03.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Abstract 1798: Mortalin precursor as potential marker for chemoprevention with SHetA2. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-1798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The flexible heteroarotinoid (Flex-Het), SHetA2, is a novel anticancer drug that induces both intrinsic and extrinsic apoptosis and autophagy in cancer cells, but not in normal cells. Protein isolation / mass spectrometry analysis using SHetA2-coupled polystyrene magnetic beads yielded three SHetA2-binding proteins all belonging to HSPA family namely, HSPA9/mortalin, HSPA8/Hsc70 and HSPA5/BiP. Mortalin, in addition to its vital chaperoning roles in other organelles of the cell, is essential for import and folding of nuclear-encoded mitochondrial proteins. The precursor form of mortalin has a 46-amino acid N-terminal region that functions as a mitochondrial localization sequence (MLS) and is cleaved by proteases after import into the mitochondrial matrix.
Hypothesis: SHetA2 binding to mortalin causes alterations that can be measured to study mechanism and monitor drug effects in animal models and clinical trials.
Methods: Western blots of whole cell or subcellular protein extracts made from cultures of normal human fallopian tube secretory or mammary epithelial cells, rat mammary tumors or human ovarian cancer cell lines treated with SHetA2 or solvent were probed with an antibody that recognizes total mortalin, a custom-made rabbit polyclonal antibody specific for the mortalin MLS (PA8238) or antibodies to loading control proteins. Immunocytochemistry using these antibodies was performed with an automated (Leica Bond III) IHC work station on cells treated with SHetA2 or solvent.
Results: Using a commercial antibody against total mortalin, we observed a lower-mobility band closely moving above the specific (mature) mortalin band in Western blots. Our mortalin MLS-specific antibody recognized only the lower-mobility band confirming it as the precursor form of mortalin in the SHetA2-treated cell extracts. Subcellular fractionation of the drug-treated cells revealed that the precursor protein accumulated only in the cytoplasm and not in the mitochondria. Staining of whole cells with an antibody to total mortalin showed no effect of SHetA2 treatment on the punctate pattern of expression consistent with mitochondrial localization. In contrast, staining with the mortalin MLS-specific antibody demonstrated that SHetA2 increased the intensity of the diffuse cytoplasmic staining consistent with localization of mortalin throughout the cytoplasm. These results were consistently observed among the various cell types.
Conclusions: SHetA2 is the only known drug that blocks the translocation of the precursor mortalin to mitochondria and its processing to mature protein. Such cytoplasmic accumulation of the precursor form of mortalin can potentially serve as pharmacodynamic endpoint to study SHetA2’s effect in laboratory experimental tumor models as well as in human clinical trials. Funding: NCI PREVENT Task Order HHSN26100002
Citation Format: Elangovan Thavathiru, Vishal Chandra, Rajani Rai, Doris Benbrook. Mortalin precursor as potential marker for chemoprevention with SHetA2 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1798. doi:10.1158/1538-7445.AM2017-1798
Collapse
|
7
|
Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study. ACTA ACUST UNITED AC 2017; 6. [PMID: 29708233 PMCID: PMC5922436 DOI: 10.7243/2050-120x-6-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Background SHetA2 is an oral anticancer agent being investigated for cancer
treatment and prevention. The aim of this study was to develop and validate
a simple, cost-effective, and sensitive HPLC-UV method for the
quantification of SHetA2 in biological samples and to apply the method to
pharmacokinetic studies of the drug. Methods Sample preparation for mouse and human plasmas involved liquid-liquid
precipitation and extraction using chilled acetonitrile with 2,
3-Diphenylquinoxaline as an internal standard. The separation of SHetA2 and
internal standard was achieved via Waters XBridge™ BEH 130 C18 (3.5
μm, 2.1×150 mm) column coupled with a Waters
XBridge™ C-18 (3.5 μm, 2.1×10 mm) guard column using
65% v/v acetonitrile: distilled water as a mobile phase in an
isocratic mode with a flow rate of 0.18 ml/min. The analytes were eluted at
a detection wavelength of 341 nm at a column temperature of
25°C. Results The method was validated across a range of 5-1000 ng/ml for SHetA2 in
plasma, with a lower limit of quantification of 5 ng/ml. The method showed
high recovery in human (79.9-81.8%) and mouse (95.4-109.2%)
plasma with no matrix effect. The intra- and inter-day accuracy and
precision studies demonstrated that the method was specific, sensitive, and
reliable. Stability studies showed that SHetA2 is stable for 20 h
postoperatively in the auto sampler, and for six weeks at -80°C in
plasma. Repetitive freezing and thawing may be avoided by preparing the
aliquots and storing them at -80°C. The developed method was
successfully applied to study the plasma pharmacokinetics of SHetA2 in
tumor-bearing nude mice after intravenous and oral administration. Conclusion A novel method for quantifying SHetA2 in mouse and human plasmas has
been validated and is being applied for pharmacokinetic evaluation of SHetA2
in tumor-bearing mice. The developed method will be utilized for the
quantification of SHetA2 in clinical studies.
Collapse
|
8
|
Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. Eur J Med Chem 2015; 96:209-17. [DOI: 10.1016/j.ejmech.2015.03.070] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Revised: 03/10/2015] [Accepted: 03/31/2015] [Indexed: 11/26/2022]
|
9
|
Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures. Cancer Invest 2014; 32:63-70. [PMID: 24499106 DOI: 10.3109/07357907.2013.877479] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Epidemiological studies suggest an association between elevated insulin levels and endometrial cancer. We studied the effects of insulin on normal endometrial cell proliferation with cytotoxicity assays. Organotypic cultures were used to determine the effects of insulin on the development of malignant histological features and anchorage independent growth. Western Blots were used to analyze the mitogen-activated protein kinases and AKT pathways. We found that insulin exerts direct effects on endometrial cells by increasing proliferation and promoting carcinogenesis. Our results suggest that this occurs through ERK 1/2 and glycogen synthase kinase-3β Ser9 phosphorylation.
Collapse
|
10
|
CAP37 activation of PKC promotes human corneal epithelial cell chemotaxis. Invest Ophthalmol Vis Sci 2013; 54:6712-23. [PMID: 24008408 DOI: 10.1167/iovs.13-12054] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
PURPOSE The objective of this study was to elucidate the signaling pathway through which cationic antimicrobial protein of 37 kDa (CAP37) mediates human corneal epithelial cell (HCEC) chemotaxis. METHODS Immortalized HCECs were treated with pertussis toxin (10 and 1000 ng/mL), protein kinase C (PKC) inhibitors (calphostin c, 50 nM and Ro-31-8220, 100 nM), phorbol esters (phorbol 12,13-dibutyrate, 200 nM and phorbol 12-myristate 13-acetate, 1 μM) known to deplete PKC isoforms, and siRNAs (400 nM) before a modified Boyden chamber assay was used to determine the effect of these inhibitors and siRNAs on CAP37-directed HCEC migration. PKCδ protein levels, PKCδ-Thr(505) phosphorylation, and PKCδ kinase activity was assessed in CAP37-treated HCECs using immunohistochemistry, Western blotting, and a kinase activity assay, respectively. RESULTS Chemotaxis studies revealed that treatment with pertussis toxin, PKC inhibitors, phorbol esters, and siRNAs significantly inhibited CAP37-mediated chemotaxis compared with untreated controls. CAP37 treatment increased PKCδ protein levels and led to PKCδ phosphorylation on residue Thr(505). Direct activation of PKCδ by CAP37 was demonstrated using a kinase activity assay. CONCLUSIONS These findings lead us to conclude that CAP37 is an important regulator of corneal epithelial cell migration and mediates its effects through PKCδ.
Collapse
|
11
|
HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4). Cell Signal 2013; 26:70-82. [PMID: 24036211 DOI: 10.1016/j.cellsig.2013.08.043] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Accepted: 08/30/2013] [Indexed: 12/13/2022]
Abstract
Human MAP3K4 (MTK1) functions upstream of mitogen activated protein kinases (MAPKs). In this study we show MTK1 is required for human epidermal growth factor receptor 2/3 (HER2/HER3)-heregulin beta1 (HRG) induced cell migration in MCF-7 breast cancer cells. We demonstrate that HRG stimulation leads to association of MTK1 with activated HER3 in MCF-7 and T-47D breast cancer cells. Activated HER3 association with MTK1 is dependent on HER2 activation and is decreased by pre-treatment with the HER2 inhibitor, lapatinib. Moreover, we also identify the actin interacting region (AIR) on MTK1. Disruption of actin cytoskeletal polymerization with cytochalasin D inhibited HRG induced MTK1/HER3 association. Additionally, HRG stimulation leads to extracellular acidification that is independent of cellular proliferation. HRG induced extracellular acidification is significantly inhibited when MTK1 is knocked down in MCF-7 cells. Similarly, pre-treatment with lapatinib significantly decreased HRG induced extracellular acidification. Extracellular acidification is linked with cancer cell migration. We performed scratch assays that show HRG induced cell migration in MCF-7 cells. Knockdown of MTK1 significantly inhibited HRG induced cell migration. Furthermore, pre-treatment with lapatinib also significantly decreased cell migration. Cell migration is required for cancer cell metastasis, which is the major cause of cancer patient mortality. We identify MTK1 in the HER2/HER3-HRG mediated extracellular acidification and cell migration pathway in breast cancer cells.
Collapse
|
12
|
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol 2013; 130:377-82. [PMID: 23632208 DOI: 10.1016/j.ygyno.2013.04.054] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2012] [Revised: 04/19/2013] [Accepted: 04/21/2013] [Indexed: 11/26/2022]
Abstract
OBJECTIVE This study aims to assess the role of polymorphisms in DNA repair genes, excision repair cross-complementation group 1 (ERCC1) and methyl-methanesulfonate sensitivity 19 (MMS19), in tumor response to platinum-based chemotherapy and survival in advanced epithelial ovarian cancer (EOC). METHODS Single nucleotide polymorphism (SNP) analysis was performed on the paraffin-embedded tumor tissue of women with advanced EOC, treated with platinum-based chemotherapy at the University of Oklahoma Health Sciences Center. Polymorphisms from two ERCC1 (codon-118 and C8092A) and three MMS19 (rs2211243, rs2236575 and rs872106) gene loci were evaluated by real time PCR Allelic Discrimination Assay. RESULTS Genotyping was performed in 107 patients, 45 platinum-sensitive and 62 platinum-resistant. ERCC1, codon-118 and C8092A genotyping was evaluable in 98 and 106 patients respectively and in all 107 patients for MMS19 polymorphisms. No differences were observed in genotype between platinum-sensitive and platinum-resistant patients. Polymorphisms in the ERCC1, codon-118 and MMS19 genes did not correlate with overall survival (OS), although a trend toward improved progression free survival (PFS) was observed in patients expressing the minor (GG) alleles of the rs872106 MMS19 gene. Women homozygous for the ERCC1-C8092A minor (AA) alleles had a significant increase in PFS compared to AC and CC patients and both AA and AC genotypes conferred improved survival over the major (CC) genotype. CONCLUSIONS Polymorphisms in ERCC1, codon-118 and MMS19 genes are not associated with clinical response to platinum or survival. The ERCC1-C8092A genotypes containing an "A" allele were associated with significant improvement in PFS and OS strengthening the value of this specific genotype in survival.
Collapse
|
13
|
Abstract 4298: microRNA-200c mediates the tumor suppressive effects of Wnt inhibitory factor 1 in human malignant salivary gland cells. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-4298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The important role of Wingless-type (Wnt)/β-catenin pathway is well established in various human tumors. Previously, we have demonstrated that Wnt inhibitory factor 1 (WIF1) is significantly downregulated in human salivary gland tumors. The tumor suppressor microRNA, miR-200c, is downregulated in many cancers and is known to repress migration and invasion of cancer cells.
Aims: To determine the tumor suppressive effects of WIF1 and delineate the mechanisms by which WIF1 regulates microRNAs in human malignant salivary gland cells.
Methods: Human malignant salivary gland cells (Carcinoma ExPleomorphic adenoma, CaExPA79) were transiently transfected with either empty vector or pCI blast-WIF1 and cell proliferation was determined by MTT assay at various time points. CaExPA79 cells transfected with WIF1 for 48 h were used for total RNA isolation and gene expression studies. To determine the effect of WIF1 restoration on salivary gland cancer cells, CaExPA79 cells were treated with 50 μM of 5-aza-2′-deoxycytidine (DAC), a demethylating agent, for 4 days. After DAC treatment, the cells were either used for cell cycle analysis or total RNA isolation and real-time RT-PCR analysis. To determine the effect of WIF1 on miR-200c, CaExPA79 cells were transfected with pCI blast-WIF1 along with miR200c-Luc reporter vector and Renilla luciferase expressing plasmid pRL-TK for 24 h. Luciferase activity was determined using Dual-Luciferase Reporter Assay System.
Results: WIF1 significantly inhibited the proliferation of CaExPA79 at 24, 48 and 72 h. Treatment with DAC increased the WIF1 mRNA expression and resulted in a significant accumulation of cells in S phase. DAC treatment also resulted in a significant increase in miR-200c expression. WIF1 over-expression resulted in a significant increase in miR-200c expression and led to a significant reduction in the expression of miR-200c targeted genes as documented by luciferase reporter gene assays. Conclusions: WIF1 inhibits salivary gland cancer cell proliferation and induces cell cycle arrest. Most importantly, our findings suggest that WIF1 is a positive transcriptional regulator of the tumor suppressor microRNA miR-200c and leads to a corresponding downregulation of its downstream targets. Taken together, this study reveals a novel mechanism by which WIF1 elicits it's tumor suppressive effects on salivary gland cancer cells.
Grant support: This work was supported by the Oklahoma Center for the Advancement of Science & Technology (LQ) (HR08-018). LQ holds a Presbyterian Health Foundation Endowed Chair in Otorhinolaryngology.
Citation Format: Ilangovan Ramachandran, David Obeso, Sripathi M. Sureban, Elangovan Thavathiru, Antonio Reis, Lurdes Queimado. microRNA-200c mediates the tumor suppressive effects of Wnt inhibitory factor 1 in human malignant salivary gland cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4298. doi:10.1158/1538-7445.AM2013-4298
Collapse
|
14
|
Abstract 3703: SHetA2 decreases mitoses and growth, and alters pathology of MNU-induced rat mammary tumors. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-3703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: SHetA2 (NSC721689) is a non-toxic chemoprevention drug that has completed pre-clinical testing by the NCI-RAID and RAPID programs and will be evaluated in a Phase 0 clinical trial under development. Previous studies found that SHetA2 reversed the cancerous phenotype and prevented carcinogenesis in organotypic cultures of human ovarian cancer and endometrial cells. The objective of this project was to evaluate the effects of oral SHetA2 on histologic features of tumors induced by the nitrosomethylurea (MNU) carcinogen in Sprague-Dawley rats.
Methods: SHetA2 was administered to 3 treatment groups of 15 animals each in a Teklad diet formulated to contain doses of 0 (control), 25 (low dose) and 50 (high dose) mg/kg/day. Five days after initiation of treatment, each rat was injected with 11.25 mg of MNU into the peritoneum and the animals were continued on their respective diets. The first palpable tumors were noted 48 days after MNU injection. Tumors volumes were measured weekly. Four animals in the control group were euthanized early on days 58, 63, 78 and 82, one animal in the low dose group was euthanized on day 78 and one animal in the high dose group was euthanized on day 74 due to the excessive sizes of their tumors. The remaining animals were euthanized on day 85 and the tumors were collected for histologic evaluation. H&E stained slides of the tumors were reviewed for histologic features in a blinded manner. A linear mixed model was used to compare the growth rate of tumor volumes. The fixed effects included treatment group and days. An unstructured covariance matrix was used in the model. The numbers of mitoses in the tumors of the different treatment groups were compared using a linear mixed model.
Results: Tumor growth rate was significantly lower in the high dose group in comparison to the control group (p=.004) and the low dose (p=.003). No significant difference (p=.716) in growth rate was observed between low dose and control groups. The number of mitoses counted in the tumors was significantly smaller in the high dose than in the control group (p=.004), but no significant difference was observed between low dose and control groups (p=.945). The histology of the tumors included fibrocystic disease, intraductal papillomatosis, adenoid cystic carcinoma, papillary carcinoma, papillary and adenoid cystic carcinoma and carcinoma. When compared per animal, there were no significant differences in the histologies between the treatment groups, however when each tumor was considered an individual data point, there was a statistical trend that both doses of SHetA2 decreased the percentage of papillary carcinoma and increased the percentages of adenoid cystic carcinoma, (high dose vs control: p=.058; low dose vs control: p=.058).
Conclusion: SHetA2 administered in the diet reduced cell proliferation, growth and aggressiveness of the pathologic diagnosis of mammary tumors in MNU-treated rats.
Citation Format: Stan Lightfoot, Daniel Zhao, Elangovan Thavathiru, Doris Mangiaracina Benbrook. SHetA2 decreases mitoses and growth, and alters pathology of MNU-induced rat mammary tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3703. doi:10.1158/1538-7445.AM2013-3703
Collapse
|
15
|
Abstract 4679: A novel assay to predict susceptibility to tobacco-induced disease. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-4679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tobacco misuse is the leading preventable cause of morbidity and mortality in the world. Tobacco-induced DNA damage is one of the main mechanisms contributing to the pathogenesis of cancer, stroke, heart and pulmonary diseases. Tobacco-induced DNA damage is modulated by genetic and epigenetic factors, as well as life-style choices, and is expected to be a major determinant of the individual susceptibility to tobacco-induced diseases.
Technical limitations allow only a few types of DNA damage to be quantified in human samples. Recently, we filled a major methodological gap in the field of DNA damage by developing a novel and highly sensitive primer-anchored DNA damage detection assay (PADDA) to map and quantify in vivo levels of DNA damage.
Aims: (1) To standardize PADDA for the detection of oxidative DNA damage, one of the main types of tobacco-induced damage. (2) To define the levels of persistent DNA damage in the oral mucosa of smokers. (3) To determine if persistent nucleotide damage at p53 co-localizes with tobacco-induced cancer mutational hotspots.
Methods: To standardize the assay, PADDA was used on a high-throughput setting to quantify DNA damage in oral cell lines exposed to very low doses of hydrogen peroxide. DNA damage was mapped and quantified on the p53 gene by PADDA in oral epithelial cells collected from smokers and non-smokers by oral scrapings. The location of p53 nucleotide damage was compared with reported tobacco-induced p53 cancer mutational hotspots. Saliva cotinine levels were used to confirm smoking status. Data were analyzed by chi-square goodness of fit and exact non-parametric tests.
Results: Our data documented PADDA's ability to detect dose-dependent increase in DNA damage in human oral cells. DNA damage was significantly higher in smokers than in non-smokers. Moreover, we documented for the first time that the persistent DNA damage in the oral mucosa of smokers has significantly higher mutagenic potential than that present in non-smokers and persists mainly at p53 nucleotides that are hotspots for mutation in tobacco-induced cancers.
Conclusion: PADDA detects dose-dependent DNA damage response, a crucial test of its accuracy and a prerequisite for its use in biomonitoring. PADDA documents the extent of tobacco-induced DNA damage in vivo, and reinforces the importance of smoking cessation. Of major clinical importance, we show, for the first time, that tobacco-induced DNA damage persists preferentially in p53 nucleotides that are hotspots for mutation. Application of this assay to large series of smokers and former smokers has a major potential to establish biomarkers of susceptibility to tobacco-induced disease, which can guide preventive and diagnostic strategies.
Funding: This work was supported by the Oklahoma Tobacco Research Center and the Oklahoma Center for the Advancement of Science & Technology. Dr. Queimado holds a Presbyterian Health Foundation Endowed Chair in Otorhinolaryngology.
Citation Format: Vengatesh Ganapathy, Wilbur K. Mills, Elangovan Thavathiru, Ilangovan Ramachandran, Leslie Chandler, Antonio Reis, Lurdes VF Queimado. A novel assay to predict susceptibility to tobacco-induced disease. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4679. doi:10.1158/1538-7445.AM2013-4679
Collapse
|
16
|
Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann Rheum Dis 2011; 71:136-42. [PMID: 21978998 DOI: 10.1136/annrheumdis-2011-200085] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
OBJECTIVES Altered signalling in B cells is a predominant feature of systemic lupus erythematosus (SLE). The genes BANK1 and BLK were recently described as associated with SLE. BANK1 codes for a B-cell-specific cytoplasmic protein involved in B-cell receptor signalling and BLK codes for an Src tyrosine kinase with important roles in B-cell development. To characterise the role of BANK1 and BLK in SLE, a genetic interaction analysis was performed hypothesising that genetic interactions could reveal functional pathways relevant to disease pathogenesis. METHODS The GPAT16 method was used to analyse the gene-gene interactions of BANK1 and BLK. Confocal microscopy was used to investigate co-localisation, and immunoprecipitation was used to verify the physical interaction of BANK1 and BLK. RESULTS Epistatic interactions between BANK1 and BLK polymorphisms associated with SLE were observed in a discovery set of 279 patients and 515 controls from northern Europe. A meta-analysis with 4399 European individuals confirmed the genetic interactions between BANK1 and BLK. As BANK1 was identified as a binding partner of the Src tyrosine kinase LYN, the possibility that BANK1 and BLK could also show a protein-protein interaction was tested. The co-immunoprecipitation and co-localisation of BLK and BANK1 were demonstrated. In a Daudi cell line and primary naive B cells endogenous binding was enhanced upon B-cell receptor stimulation using anti-IgM antibodies. CONCLUSION This study shows a genetic interaction between BANK1 and BLK, and demonstrates that these molecules interact physically. The results have important consequences for the understanding of SLE and other autoimmune diseases and identify a potential new signalling pathway.
Collapse
|
17
|
Abstract C21: Wnt inhibitory factor 1 is silenced by promoter hypermethylation in cervical cancer and its restoration suppresses tumor growth. Cancer Res 2011. [DOI: 10.1158/1538-7445.fbcr11-c21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Purpose: Cervical cancer is the leading cause of morbidity and mortality among women worldwide. It is also the second most common cause of cancer deaths in women. Recent studies suggest that aberrant activation of the Wingless-type (Wnt) pathway plays an important role in cervical cancer. However, the mechanisms and implications of Wnt activation in human cervical cancer are yet to be determined. We hypothesized that the Wnt inhibitory factor 1 (WIF1), a secreted Wnt antagonist, might be silenced in human cervical cancer. Therefore, we characterized the methylation status of WIF1 gene, its mRNA and protein expression in human cervical cancer samples. We also determined the effects of WIF1 treatment on tumor growth in a xenograft mouse model.
Methods: To study WIF1 promoter methylation, genomic DNA was isolated from human normal and cancerous cervical samples, processed for bisulfite modification using EZ DNA methylation kit and WIF1 methylation-specific PCR was performed. WIF1 mRNA and protein expression in human cervical normal epithelium and tumor samples were assessed by real-time RTPCR and immunohistochemistry, respectively. To determine the tumor suppressive effects of WIF1, tumor xenograft studies were performed by injecting HeLa cells subcutaneously into the flanks of nude mice. Palpable tumors were treated for 7 weeks with peritumoral injection of pCI-blast-WIF1 expression vector that expresses the full WIF1 protein.
Results: Our study demonstrates that WIF1 promoter hypermethylation is a frequent mechanism leading to WIF1 down-regulation as observed by decreased WIF1 mRNA and protein expression in cervical cancer compared with normal tissue. Furthermore, treatment of human cervical cancer in a xenograft mouse model by WIF1 gene transfer significantly inhibited the tumor growth by decreasing the expression of TCF-4, β-catenin, c-myc, cyclin D1 and CD44. WIF1 elicited its tumor suppressive effects by acting at multiple levels in Wnt/β-catenin pathway, in addition to modulating the expression of antiapoptotic (Bcl-2) and apoptotic proteins (p53, p21 and caspase-3), leading to a significant reduction in tumor cell proliferation and induction of massive apoptosis. Of major clinical relevance, while vector treated tumors were highly infiltrative, WIF1 treated tumors presented mainly with pushing borders, a characteristic feature of benign tumors. In addition, WIF1 treatment decreased the expression of angiogenic factors, VEGF and CD31, and significantly reduced the tumor vascular irrigation.
Conclusions: Our findings for the first time demonstrate that WIF1 is silenced by promoter hypermethylation and identify WIF1 down-regulation as an important mechanism of Wnt activation in cervical cancer. Remarkably, our in vivo study emphasizes the anti-invasive, anti-angiogenic and tumor suppressive effects of WIF1 and therefore its potential therapeutic value in the treatment of cervical cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr C21.
Collapse
|
18
|
Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol Carcinog 2005; 44:174-82. [PMID: 16187332 PMCID: PMC4166602 DOI: 10.1002/mc.20122] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Common chromosomal fragile sites are unstable genomic loci susceptible to breakage, rearrangement, and are highly recombinogenic. Frequent alterations at these loci in tumor cells led to the hypothesis that they may contribute to cancer development. The two most common chromosomal fragile sites FRA16D and FRA3B which harbor WWOX and FHIT genes, respectively, are frequently altered in human cancers. Here we report that environmental carcinogens, ultraviolet (UV) light, and Benzo[a]pyrene diol epoxide (BPDE), significantly downregulate expression of both genes. On the other hand, we observe that ionizing radiation (IR) does not affect expression of these genes, suggesting that the effect of repression exerted by UV and BPDE is not just a consequence of DNA damage but may be a result of different signaling pathways triggered by specific DNA lesions. Such downregulation correlates with an induction of an S-phase delay in the cell cycle. Treatment of UV-irradiated cells with caffeine abrogates the S-phase delay while concomitantly overcoming the repression phenomenon. This suggests the involvement of unique cell cycle checkpoint mechanisms in the observed repression. Therefore, it is hypothesized that protracted downregulation of the putative tumor suppressor genes WWOX and FHIT by environmental carcinogens may constitute an additional mechanism of relevance in the initiation of tumorigenesis.
Collapse
|
19
|
Activation of pRL-TK by 12S E1A oncoprotein: drawbacks of using an internal reference reporter in transcription assays. Biotechniques 2001; 31:528-30, 532. [PMID: 11570496 DOI: 10.2144/01313st06] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
In transient expression assays for transcription, a vector carrying the experimental reporter is usually co-transfected with a second vector containing a distinct reporter gene as a control. The second reporter is linked to a constitutive promoter driving a low-level transcription that is unresponsive to the experimental trans-acting transcription factors used. The use of dual reporters enables the normalization of the experimental gene transcription with respect to the control reporter transcription. This method is expected to minimize the inherent variability in transfection data caused by changes in cell density and viability, cell lysis, and the recovery of samples at various stages of the experiment. Here, we report that one of the most widely used internal control reporters, the Renilla luciferase plasmid (pRL-TK), is unresponsive to human tumor suppressor protein p53, a potent transcriptional regulator; however, the reporter transcription is enhanced by another well-known transcriptional regulator, the adenoviral 125 EIA oncoprotein, thereby disqualifying pRL-TK as a universal internal control reporter for transcription assays. Our results reveal the necessity of stringent experiments to test the responsiveness of internal control plasmids to transcriptional regulators present in the assay to avoid the misinterpretation of transcriptional analysis data.
Collapse
|
20
|
Abundant secretory lipocalins displaying male and lactation-specific expression in adult hamster submandibular gland. cDNA cloning and sex hormone-regulated repression. EUROPEAN JOURNAL OF BIOCHEMISTRY 1999; 266:467-76. [PMID: 10561587 DOI: 10.1046/j.1432-1327.1999.00884.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We have previously identified massively expressed 24- and 20.5-kDa male-specific proteins in submandibular salivary glands (SMG) of adult hamsters. Here we report the cloning of the cDNA encoding the 24-kDa protein which we have now found to be a heterogenously N-glycosylated form of the 20.5-kDa protein. The deduced amino acid sequence indicated that the protein is a member of the lipocalin family, the two most related lipocalins being rat odorant-binding protein of nasal mucosa and aphrodisin, a pheromonal protein present in vaginal discharge and saliva of female hamsters. Northern blot analysis showed that cognate mRNA is expressed in hamster SMG and lacrimal gland (LG) displaying marked sex-hormonal repression. The sex-hormonal repression patterns showed similarities and dissimilarities between SMG and LG but they were, respectively, similar to the sex-hormonal repression pattern noted for the SMG 24/20.5-kDa male-specific proteins and for an abundant female-specific 20-kDa LG secretory protein. These SMG and LG proteins were found to be immunologically similar and secretion of the SMG proteins in saliva and their excretion in urine was detected. The male-specific and abundant expression of the SMG proteins were seen at and after sexual maturity but was not dependent on androgens. Surprisingly, a temporary male-like expression of these SMG proteins was seen in lactating females which was obliterated by oestrogen administration. Our results show that despite differences in their repression by sex hormones, the gene for SMG 24/20.5-kDa proteins is similar or identical to that of LG 20-kDa protein and their marked repression by both androgens and oestrogens might be at the transcriptional level. Moreover, they might be excellent models with which to study sex hormone repression of gene expression at the molecular level. The results of homology search and the male- and lactation-specific pressure of the SMG proteins in adult saliva and urine suggests a possibility of their involvement in olfaction-mediated chemical communication between hamsters.
Collapse
|